Search

Search Constraints

You searched for: Author/Creator Press, Oliver W.

Search Results

1. A multicentre study of primary breast diffuse large B‐cell lymphoma in the rituximab era. (27th January 2014)

2. A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. (29th January 2013)

3. A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab (Anti‐CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma. Issue 7 (22nd April 2020)

4. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. Issue 1 (January 2015)

5. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. (14th September 2018)

6. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. Issue 9 (October 2015)

7. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. Issue 9 (October 2015)

8. Brentuximab vedotin administered to platinum‐refractory, transplant‐naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Issue 4 (18th September 2014)

10. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Issue 2 (1st February 2017)